The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

Amphista Therapeutics has reported preclinical leukemia data on its protein degrader, positioning the Big Pharma-partnered biotech to target a 2026 start date for a phase 1 clinical trial. The data, ...

A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.

Compared with white patients, Black patients with an aggressive form of leukemia—called acute myeloid leukemia (AML)—were on ...

Know how sandbox environments help businesses test large-scale stablecoin usage. Learn how to assess transaction volume, ...

Treatment with bleximenib and Venclexta (venetoclax) showed a tolerable safety profile in a phase 1b trial for patients with ...

Online retailers are increasingly being targeted by money laundering schemes, as criminal networks exploit refunds, ...

At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.

Compared with white patients, Black patients with an aggressive form of leukemia--called acute myeloid leukemia (AML)--were ...

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

As cryptocurrencies become increasingly integrated into global commerce, businesses of all sizes face a growing need to protect themselves from hidden risks within the blockchain ecosystem.